Tab-cel for solid organ or allogeneic transplant recipients with EBV-PTLD

Update on ALLELE: tab-cel in patients with EBV+ PTLD following alloSCT after rituximab failureПодробнее

Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD)Подробнее

Long-term outcomes of subjects with EBV driven PTLD following solid organ or allogeneic HCT trea...Подробнее

Strategies for the management of EBV-PTLDПодробнее

Tabelecleucel in the treatment of EBV+ PTLDПодробнее

Tabelecleucel for treating EBV associated PTLDПодробнее

Advances in EBV-PTLDПодробнее

Tabelecleucel in EBV-associated PTLDПодробнее

Clinical outcomes of patients with EBV-PTLD who fail rituximab following HSCTПодробнее

The treatment and management of PTLDПодробнее

Mohamad Mohty, ASH 2018 – Epstein-Barr virus and cytotoxic T lymphocyte therapyПодробнее

PTLDПодробнее

Management of Malignancies Pre and Post TransplantПодробнее

Atara BiotherapeuticsПодробнее

Dr. Prockop Discusses Tabelecleucel in Post-Transplant EBV+ LymphomasПодробнее

Tabelecleucel as an alternative treatment option in patients following transplantationПодробнее

Promising therapeutic efficacy of EBV-specific T-cell immunotherapy tabelecleucel in PTLDПодробнее

PTLDПодробнее

Association of antiviral prophylaxis and rituximab use with PTLDsПодробнее